What will new weight loss medicines bring to people with type 2 diabetes?
While the new generation of available weight management medications are the most effective...
Read Moreby Dr. Sue Pedersen | Oct 5, 2026 | Media, Research, Uncategorized | 0
While the new generation of available weight management medications are the most effective...
Read Moreby Dr. Sue Pedersen | Aug 7, 2026 | Media, Uncategorized | 0
Well this is a first in the obesity world. In USA, the FDA has provided guidance to drugmaker Eli...
Read Moreby Dr. Sue Pedersen | Jul 27, 2026 | Media, Uncategorized | 0
As blogged previously, retatrutide is a GLP1, glucagon, and GIP (‘triple G’) agonist...
Read Moreby Dr. Sue Pedersen | Jul 23, 2026 | Media, Uncategorized | 0
There’s a lot of chatter in the virtual space these days about microdosing GLP1 medicines...
Read Moreby Dr. Sue Pedersen | Jul 4, 2026 | Media, Uncategorized | 0
Hot on the heels of the first generic Ozempics (semaglutide for type 2 diabetes), the first...
Read Moreby Dr. Sue Pedersen | May 25, 2026 | Media, Uncategorized | 0
Retatrutide is a ‘triple G’ agonist of the GLP1, glucagon, and GIP receptors. As...
Read Moreby Dr. Sue Pedersen | Apr 30, 2026 | Media, Uncategorized | 0
The first generic semaglutide has been approved by Health Canada, and it’s got everyone...
Read Moreby Dr. Sue Pedersen | Dec 12, 2025 | Media, Research, Uncategorized | 0
Listen here, or read below! Well this is exciting indeed! The topline results of the TRIUMPH-4...
Read Moreby Dr. Sue Pedersen | Nov 15, 2025 | Media, Uncategorized | 0
As we advance the field of obesity medicine, headlines around weight loss medication studies...
Read Moreby Dr. Sue Pedersen | Aug 11, 2025 | Media, Uncategorized | 0
I am so deeply honored – and excited! – to share with you that we have now published...
Read Moreby Dr. Sue Pedersen | Aug 3, 2025 | Diabetes, Media, Research, Uncategorized | 0
In choosing the best GLP1-based medication for our patients with type 2 diabetes at high risk of...
Read Moreby Dr. Sue Pedersen | Jun 22, 2025 | Diabetes, Media, Research, Uncategorized | 0
Our natural human biology vigourously defends our body weight, in part because we have many...
Read More

I am a medical doctor, Specialist in Endocrinology & Metabolism, a Diplomate of the American Board of Obesity Medicine, and a Clinical Lecturer at the University of Calgary, Canada. After completing my training as an Endocrinologist in 2005 at the University of Calgary, I have worked in Calgary, at the Royal University Hospital in Saskatchewan, and at the University of Copenhagen in Denmark. I have a busy clinical practice at C-ENDO Diabetes and Endocrinology Clinic in Calgary, caring for patients with diabetes, obesity, thyroid, and other hormone issues. I am also involved in clinical research in diabetes and obesity. I am the lead author of the 2020 and 2022 Pharmacotherapy Chapters of the Canadian Obesity Clinical Practice Guidelines, and a member of the Expert Committee for the Diabetes Canada Clinical Practice Guidelines as an author on the Weight Management chapter. I am passionate, enthusiastic, and driven to help conquer the stigma against obesity; educate health care professionals and the public about obesity and diabetes; and to help us become a healthier society!